FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More
Executive Summary
Agency says "some credible evidence" suggests intake of EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.
You may also be interested in...
Researchers Suggest 3 Grams Omega-3s Daily Optimal, But Don't Back Allowing Health Claim
A meta-analysis of studies comprising almost 5,000 participants showed a promising link between a 3-gram daily dose of omega-3s and lower blood pressure in adults with and without high blood pressure.
US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name
National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.
Magnesium Qualified Health Claims For Reducing Risk Of Hypertension Authorized In US
CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.